Abstract
Background Re-purposing of existing drugs for the treatment of COVID-19 might be an effective alternative during the pandemic.
Objective To determine the association of the risk of COVID-19 and the drugs which have been suggested to have therapeutic effects against or increase the susceptibility to SARS-CoV-2.
Design A case control study using a nationwide claims database. Exposure was defined as a prescription of study drugs which would have been continued until 7 days prior to test for COVID-19 or later.
Setting South Korea, where a large testing capacity was available throughout the course of the epidemic.
Participants Adults aged 18 years or older who were tested for COVID-19.
Measurements The diagnosis of COVID-19.
Results Among 65,149 subjects included (mean age, 48.3 years; 49.4% male), 5,172 (7.9%) were diagnosed of COVID-19. Hydroxychloroquine showed no significant association with the risk for COVID-19 (adjusted odds ratio [aOR], 1.48; 95% CI, 0.95–2.31). Camostat (aOR, 0.45; 95% CI, 0.20–1.02) and amiodarone (aOR, 0.54; 95% CI, 0.33–0.89) were associated with a lower risk for COVID-19 in overall population, but the difference did not reach statistical significance in subgroup analysis. Angiotensin receptor blocker was associated with a small increase in the risk (aOR, 1.13; 95% CI, 1.01–1.26), which was not observed in subgroup analysis.
Limitations A possibility of bias in the characteristics of controls; information on drug compliance and the severity of underlying conditions could not be obtained.
Conclusions No medications included in our study was consistently associated with a risk for COVID-19. These findings suggest that more cautious approach is warranted for the clinical use of re-purposed drugs until the results from clinical trials are available.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by grants from the Gachon University Gil Medical Center (grant nos. 2018-17 and 2019-11). The sponsor of the study was not involved in the study design, analysis, and interpretation of data; writing of the report; or the decision to submit the study results for publication.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The analysis code is included as a supplement. You can use it freely. Raw data is held by the Korea Health Insurance Review and Assessment Service. You can use it via # opendata4covid19.
